CompletedNot Applicable

Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

United States20 participantsStarted 2009-05

Plain-language summary

This research study is studying identification of de novo Fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to Fanconi anemia in patients with acute myeloid leukemia.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Treated on COG-2961 or COG-AAML03P1 * At high risk of having Fanconi anemia, defined as meeting one the following groups of clinical criteria: * Group 1: Prolonged neutropenia after induction, severe regimen-related toxicity (mucositis, veno-occlusive disease, end-organ damage) * Group 2: Early non-relapse death (induction, consolidation) * Group 3: Small-for-weight, secondary malignancies

What they're measuring

Identification of children at high risk of having Fanconi anemia

Timeframe: Up to 5 months

Identification of Fanconi anemia patients

Timeframe: Up to 5 months

Trial details

NCT IDNCT01146210

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Childhood Acute Erythroleukemia (M6) trials